Medicines and Healthcare products Regulatory Agency's (MHRA)
decision comes after the European medicines agency added GBS as a
possible side-effect last month.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Shinjini
Ganguli)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights
reserved. This material may not be published, broadcast, rewritten
or redistributed.
Thompson Reuters is solely responsible for this content |